7 April, 2016
A randomized controlled multi-center study performed in Sweden for treatment of idiophatic rhinitis with kinetic oscillations has been published online by Acta Oto-laryngologica after peer review.
Two hundred and seven patients (207) were randomized in the study, including five visits and lasting for ~25 weeks. All patients had two treatments episodes, and all patients had at least one treatment meant as active, with high amplitude pressure for 10 min in each nostril.
Results: KOS treatment with high amplitude pressure did not have significant beneficial effects as compared to low amplitude pressure on TVRSS. Numerical improvements in TVRSS and SNOT 22 were found when comparing high and low amplitude pressure treatments with uninflated balloon treatmen. However, this part of the study was initially single blinded, and these results were secondary objectives.
Anders Ehnhage, Pernilla Sahlstrand Johnsson, Cecilia AhlströmEmanuelsson, Morgan Andersson, Johan Knutsson, Jacob Lien, Tomas Norlander, Petter Olsson, Jan-Eric Friis-Liby & Mats Holmström (2016): Treatment of idiopathic rhinitis with kinetic oscillations – a multi-centre randomized controlled study, Acta Oto-Laryngologica.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.